> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Genentech’s Ocrevus
- URL: https://www.fdaweb.com/regulatory-review-period-for-genentechs-ocrevus/
- Published: 2018-10-19T12:00:00.000Z
- Updated: 2026-09-15T00:39:18.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142632

*Federal Register* notice: FDA has determined for patent extension-related purposes the regulatory review period for Genentech’s Ocrevus (ocrelizumab), indicated for treating patients with relapsing or primary progressive forms of multiple sclerosis. The regulatory review period is 4,844 days, including 4,509 days that occurred during the testing phase and 335 days during the approval phase. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-10-18/pdf/2018-22699.pdf?ref=fdaweb.com).